Table 1 Demographic and clinical characteristics of the study population. All data are reported for n = 142 participants at the time of the first serology assay, unless otherwise stated
Variable | Value |
|---|---|
Age (years) | |
Mean (SD) | 71.1 (13.1) |
Median [IQR] | 74.0 (64.0; 81.0) |
Range | (32.0; 93.0) |
Sex, n (%) | |
Females | 39 (27.5%) |
Males | 103 (72.5%) |
BMI (kg/m2) | |
Mean (SD) | 25.3 (5.5) |
Median [IQR] | 24.2 (21.7; 27.4) |
Range | (14.4; 54.2) |
Diabetes, n (%) | 61 (43.0) |
Immunosuppressant treatment, n (%) | 21 (14.8) |
On the French national waiting list for kidney transplantation, n (%) | 48 (33.8) |
Time on dialysis (months) | |
Mean (SD) | 69.0 (93.4) |
Median [IQR] | 34.6 (11.1; 85.2) |
Range | (0.2; 439.2) |
Kt/V | |
Mean (SD) | 1.5 (0.3) |
Median [IQR] | 1.5 (1.3; 1.7) |
Range | (0.6; 2.2) |
Time interval between the first vaccine dose and Ser1 (n = 126) | |
Mean (SD) | 62.2 (28.9) |
Median [IQR] | 75.0 (71.0; 76.0) |
Range | (−4.0; 78.0) |
Time interval between the second vaccine dose and Ser1 (n = 115) | |
Mean (SD) | 45.7 (18.1) |
Median [IQR] | 50.0 (50.0; 54.0) |
Range | (− 55.0; 57.0) |
Time interval between the third vaccine and Ser2 (n = 100) | |
Mean (SD) | 35.0 (0.1) |
Median [IQR] | 35.0 (35.0; 35.0) |
Range | (35.0; 36.0) |
Leukocyte count (× 109/L) | |
Mean (SD) | 7.4 (2.7) |
Median [IQR] | 7.0 (5.5; 8.7) |
Range | (2.5; 20.7) |
Lymphocyte count (× 106/L) | |
Mean (SD) | 1573.7 (1149.2) |
Median [IQR] | 1410.0 (1049.0; 1821.0) |
Range | (242.0; 12,479.0) |
Serum albumin (g/l) | |
Mean (SD) | 41.3 (3.3) |
Median [IQR] | 41.0 (39.0; 44.0) |
Range | (32.0; 48.0) |